Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02761187 · ClinicalTrials.gov registry record
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
A clinical trial, sponsored by Takeda.
- Terminated
- Registry status
- 4,253
- Enrollment target
NCT02761187 is a clinical trial that was terminated before completion, run by Takeda. The registered enrollment target is 4,253 participants.
The verdict
NCT02761187 was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- 4,253 participants
- Enrollment target
Study Summary
The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed \[ND\] multiple myeloma (MM) and participants with relapsed/refractory \[R/R\] MM.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,253 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2021-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02761187
The ClinicalTrials.gov registry entry for NCT02761187 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4,253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT02761187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02761187 about?
NCT02761187 is a clinical study titled "An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants". The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed \[ND\] multiple myeloma (MM) and participants with relapsed/refractory \[R/...
What is the current status of trial NCT02761187?
This trial is currently terminated. The enrollment target is 4,253 participants. The study started on 2016-07-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT02761187?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT02761187?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.